exg110
Gene therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 16, 2024 (NCT06539624)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-galactosidase ASupplementation
GLA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06819514 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2025 | Government of China, People's Liberation Army of China |
| NCT06539624 | N/A | Oct 16, 2024 | Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1